TY - JOUR
T1 - Design, Synthesis, and In Vitro Evaluation of Carbamate Derivatives of 2-Benzoxazolyl- and 2-Benzothiazolyl-(3-hydroxyphenyl)-methanones as Novel Fatty Acid Amide Hydrolase Inhibitors
AU - Myllymäki, Mikko J.
AU - Saario, Susanna M.
AU - Kataja, Antti O.
AU - Castillo-Melendez, Joel A.
AU - Nevalainen, Tapio
AU - Juvonen, Risto O.
AU - Järvinen, Tomi
AU - Koskinen, Ari M.P.
PY - 2007
Y1 - 2007
N2 - Fatty acid amide hydrolase (FAAH) is an intracellular serine hydrolase, which catalyzes the hydrolysis of the endocannabinoid N-arachidonoylethanolamide to arachidonic acid and ethanolamine. FAAH also hydrolyzes another endocannabinoid, 2-arachidonoylglycerol (2-AG). However, 2-AG has been assumed to be hydrolyzed mainly by monoacylglycerol lipase (MAGL) or a MAGL-like enzyme. Inhibition of FAAH or MAGL activity might lead to beneficial effects in many physiological disorders such as pain, inflammation, and anxiety due to increased endocannabinoid-induced activation of cannabinoid receptors CB1 and CB2. In the present study, a total of 34 novel compounds were designed, synthesized, characterized, and tested against FAAH and MAGL-like enzyme activity. Altogether, 16 compounds were found to inhibit FAAH with half-maximal inhibition concentrations (IC50) between 28 and 380 nM. All the active compounds belong to the structural family of carbamates. Compounds 14 and 18 were found to be the most potent FAAH inhibitors, which may serve as lead structures for novel FAAH inhibitors.
AB - Fatty acid amide hydrolase (FAAH) is an intracellular serine hydrolase, which catalyzes the hydrolysis of the endocannabinoid N-arachidonoylethanolamide to arachidonic acid and ethanolamine. FAAH also hydrolyzes another endocannabinoid, 2-arachidonoylglycerol (2-AG). However, 2-AG has been assumed to be hydrolyzed mainly by monoacylglycerol lipase (MAGL) or a MAGL-like enzyme. Inhibition of FAAH or MAGL activity might lead to beneficial effects in many physiological disorders such as pain, inflammation, and anxiety due to increased endocannabinoid-induced activation of cannabinoid receptors CB1 and CB2. In the present study, a total of 34 novel compounds were designed, synthesized, characterized, and tested against FAAH and MAGL-like enzyme activity. Altogether, 16 compounds were found to inhibit FAAH with half-maximal inhibition concentrations (IC50) between 28 and 380 nM. All the active compounds belong to the structural family of carbamates. Compounds 14 and 18 were found to be the most potent FAAH inhibitors, which may serve as lead structures for novel FAAH inhibitors.
KW - 2-Arachidonoylglycerol (2-AG)
KW - central nervous system
KW - enzyme inhibitor
KW - fatty acid amide hydrolase (FAAH)
KW - monoacylglycerol lipase (MAGL)
KW - N-Arachidonoylethanolamine (AEA)
KW - 2-Arachidonoylglycerol (2-AG)
KW - central nervous system
KW - enzyme inhibitor
KW - fatty acid amide hydrolase (FAAH)
KW - monoacylglycerol lipase (MAGL)
KW - N-Arachidonoylethanolamine (AEA)
KW - 2-Arachidonoylglycerol (2-AG)
KW - central nervous system
KW - enzyme inhibitor
KW - fatty acid amide hydrolase (FAAH)
KW - monoacylglycerol lipase (MAGL)
KW - N-Arachidonoylethanolamine (AEA)
U2 - 10.1021/jm070501w
DO - 10.1021/jm070501w
M3 - Article
VL - 50
SP - 4236
EP - 4242
JO - JOURNAL OF MEDICINAL CHEMISTRY
JF - JOURNAL OF MEDICINAL CHEMISTRY
SN - 0022-2623
IS - 17
ER -